

Deborah D Stocken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1452008/publications.pdf>

Version: 2024-02-01

99
papers

14,041
citations

66343

42
h-index

40979

93
g-index

102
all docs

102
docs citations

102
times ranked

14812
citing authors

#	ARTICLE	IF	CITATIONS
1	Early phase clinical trials extension to guidelines for the content of statistical analysis plans. <i>BMJ, The</i> , 2022, 376, e068177.	6.0	12
2	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	1.6	65
3	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. <i>Heart</i> , 2021, 107, 381-388.	2.9	12
4	Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-118.	2.8	5
5	Systematic review of radiological cervical foraminal grading systems. <i>Neuroradiology</i> , 2021, 63, 305-316.	2.2	13
6	Systematic review of interventions to increase the use of arteriovenous fistulae and grafts in incident haemodialysis patients. <i>Journal of Vascular Access</i> , 2021, , 112972982110069.	0.9	1
7	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology, The</i> , 2021, 3, e337-e346.	3.9	24
8	Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double-blind placebo-controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 2024-2033.	2.3	1
9	TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. <i>Trials</i> , 2021, 22, 433.	1.6	1
10	Non-invasive, vagus nerve stimulation to reduce ileus after colorectal surgery: protocol for a feasibility trial with nested mechanistic studies. <i>BMJ Open</i> , 2021, 11, e046313.	1.9	0
11	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	1.6	4
12	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	12.8	23
13	Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial. <i>BMJ, The</i> , 2021, 372, m4903.	6.0	28
14	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Therapeutics Update (BADB) cohort study). <i>BMJ</i> , 2021, 372, n1111.	10.1	50
15	Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095793.	2.0	2
16	Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 249.	7.4	33
17	PERSONALISED RATE-RESPONSE PROGRAMMING IMPROVES LONG-TERM EXERCISE TOLERANCE IN PEOPLE WITH PACEMAKER DEVICES AND HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2020, 75, 318.	2.8	0
18	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. <i>Medicine (United States)</i> , 2020, 99, e20458.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Nasal Airway Obstruction Study (NAIROS): a phase III, open-label, mixed-methods, multicentre randomised controlled trial of septoplasty versus medical management of a septal deviation with nasal obstruction. <i>Trials</i> , 2020, 21, 179.	1.6	7
20	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.7	6
21	Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure. <i>Circulation</i> , 2020, 141, 1693-1703.	1.6	12
22	Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study" • <i>Circulation</i> , 2020, 142, e319-e320.	1.6	0
23	Meta-analysis of fenestrated endovascular aneurysm repair versus open surgical repair of juxtarenal abdominal aortic aneurysms over the last 10 years. <i>BJS Open</i> , 2019, 3, 572-584.	1.7	67
24	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e028613.	1.9	2
25	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	4.1	30
26	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
27	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 663-673.	10.7	773
28	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	2.9	128
29	Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. <i>ERJ Open Research</i> , 2019, 5, 00110-2019.	2.6	9
30	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019, 9, e032165.	1.9	27
31	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 1069-1076.	1.5	74
32	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.7	60
33	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. <i>Hepatology</i> , 2018, 68, 1487-1497.	7.3	48
34	Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPASS Randomized Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 1600-1607.	8.6	58
35	Drizzling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. <i>Archives of Disease in Childhood</i> , 2018, 103, 371-376.	1.9	29
36	An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. <i>British Journal of Dermatology</i> , 2018, 179, 63-71.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients'™ Medication Beliefs and Habit Strength. <i>Journal of Investigative Dermatology</i> , 2018, 138, 785-794.	0.7	48
38	Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 25-36.	8.1	113
39	Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study. <i>BMJ Open</i> , 2018, 8, e020337.	1.9	7
40	Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib. <i>JAMA Dermatology</i> , 2018, 154, 913.	4.1	14
41	Laryngeal dysplasia and narrow band imaging: Secondary analysis of published data supports the role in patient follow-up. <i>Clinical Otolaryngology</i> , 2018, 43, 1439-1442.	1.2	5
42	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
43	Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE) <i>TJ ETQq1 1 0.784314 rgBT6/Overlook</i>		
44	Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-144.	2.8	19
45	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 565-575.	8.1	362
46	Doxycycline: a first-line treatment for bullous pemphigoid?. <i>Lancet</i> , The, 2017, 389, 1586-1588.	13.7	9
47	Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 111.	1.6	6
48	Innovations in Practice: A case control and follow-up study of 'hard to reach'™ young people who suffered from multiple complex mental disorders. <i>Child and Adolescent Mental Health</i> , 2017, 22, 49-57.	3.5	1
49	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2337.	7.4	290
50	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4006-4006.	1.6	142
51	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0175717.	2.5	46
52	Surveillance versus ablation for incidentally diagnosed small renal tumours: the SURAB feasibility RCT. <i>Health Technology Assessment</i> , 2017, 21, 1-68.	2.8	11
53	The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1039-1050.	3.7	54
54	A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): study protocol. <i>Pilot and Feasibility Studies</i> , 2016, 2, 29.	1.2	8

#	ARTICLE	IF	CITATIONS
55	TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 175.	1.6	8
56	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet</i> , The, 2016, 387, 679-690.	13.7	1,397
57	Development of guidance for statistical analysis plans (SAPs) for clinical trials. <i>Trials</i> , 2015, 16, .	1.6	2
58	Prevalence and socio-demographic correlates of cooking skills in UK adults: cross-sectional analysis of data from the UK National Diet and Nutrition Survey. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2015, 12, 99.	4.6	63
59	The NAational randomised controlled Trial of Tonsillectomy IN Adults (NATTINA): a clinical and cost-effectiveness study: study protocol for a randomised control trial. <i>Trials</i> , 2015, 16, 263.	1.6	19
60	A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial. <i>Trials</i> , 2015, 16, .	1.6	2
61	REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. <i>BMI Open</i> , 2015, 5, e007700-e007700.	1.9	28
62	Response to Comment on Little et al. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPASS). <i>Diabetes Care</i> 2014;37:2114-2122. <i>Diabetes Care</i> , 2014, 37, e272-e273.	8.6	2
63	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 2277-2282.	6.4	9
64	Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPASS). <i>Diabetes Care</i> , 2014, 37, 2114-2122.	8.6	183
65	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	1.6	351
66	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. <i>BMJ Open</i> , 2013, 3, e003995.	1.9	41
67	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. <i>Cancer Research</i> , 2013, 73, 1676-1688.	0.9	159
68	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. <i>British Journal of Cancer</i> , 2013, 109, 2453-2461.	6.4	6
69	Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. <i>British Journal of Cancer</i> , 2012, 106, 1431-1438.	6.4	23
70	The Value of Source Data Verification in a Cancer Clinical Trial. <i>PLoS ONE</i> , 2012, 7, e51623.	2.5	58
71	Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1419-1430.	4.2	506
72	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1073.	7.4	1,206

#	ARTICLE	IF	CITATIONS
73	Cholecystectomy in a Trial of Adjuvant Chemotherapy After Pancreatic Cancer Resectionâ€”Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2590.	7.4	0
74	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	1.6	708
75	Establishing the added benefit of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme. BMC Cancer, 2009, 9, 36.	2.6	6
76	Orlistat for overweight subjects with nonalcoholic steatohepatitis. Hepatology, 2009, 50, 321-321.	7.3	0
77	Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancerâ€”Subset analysis of the ESPACâ€”1 data. International Journal of Cancer, 2009, 124, 2960-2965.	5.1	32
78	Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer, 2009, 100, 246-250.	6.4	193
79	Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2008, 15, 2061-2061.	1.5	0
80	Modelling prognostic factors in advanced pancreatic cancer. British Journal of Cancer, 2008, 99, 883-893.	6.4	117
81	Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer. Archives of Surgery, 2008, 143, 75.	2.2	275
82	Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. British Journal of Cancer, 2007, 97, 971-977.	6.4	70
83	A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin. Annals of Surgical Oncology, 2007, 14, 2088-2096.	1.5	204
84	The case for adjuvant chemotherapy in pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 383-401.	2.4	15
85	Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. British Journal of Cancer, 2005, 92, 1372-1381.	6.4	325
86	Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial. Digestive Surgery, 2005, 22, 353-363.	1.2	68
87	Cationic Trypsinogen Mutations and Pancreatitis. Clinics in Laboratory Medicine, 2005, 25, 39-59.	1.4	17
88	The commercialization of clinical research: who pays the piper, calls the tune?. Family Practice, 2004, 21, 335-336.	1.9	3
89	A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. British Journal of Cancer, 2004, 91, 844-849.	6.4	98
90	Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. British Journal of Cancer, 2004, 90, 2106-2111.	6.4	71

#	ARTICLE	IF	CITATIONS
91	Cationic trypsinogen mutations and pancreatitis. <i>Gastroenterology Clinics of North America</i> , 2004, 33, 767-787.	2.2	29
92	Clinical and genetic characteristics of hereditary pancreatitis in Europe. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 252-261.	4.4	543
93	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1200-1210.	27.0	2,442
94	Progress by Collaboration: ESPAC Studies. , 2004, , 57-69.		0
95	A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2003, 89, 1860-1864.	6.4	10
96	Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival. <i>Journal of Clinical Oncology</i> , 2003, 21, 4009-4015.	1.6	48
97	Adjuvant therapy in pancreatic cancer: historical and current perspectives. <i>Annals of Oncology</i> , 2003, 14, 675-692.	1.2	115
98	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. <i>Lancet, The</i> , 2001, 358, 1576-1585.	13.7	1,019
99	Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial. <i>Annals of Surgery</i> , 2001, 234, 758-768.	4.2	560